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Abstract
Significance: Derived from the inner cell mass of the preimplantation embryo, embryonic stem cells are pro-
totype pluripotent stem (PS) cells that have the ability of self-renewal and differentiation into almost all cell
types. Exploration of the mechanisms governing this pluripotency is important for understanding reprogram-
ming mechanisms and stem cell behavior of PS cells and can lead to enhancing reprogramming efficiency and
other applications. Recent Advances: Induced pluripotent stem cells are recently discovered PS cells that can be
derived from somatic cells by overexpression of pluripotency-related transcription factors. Recent studies have
shown that transcription factors and their epigenetic regulation play important roles in the generating, main-
taining, and differentiating these PS cells. Recent advances in sequencing technologies allow detailed analysis of
target epigenomes and microRNAs (miRs), and have revealed unique epigenetic marks and miRs for PS cells.
Critical Issues: Epigenetic modifications of genes include histone modifications, DNA methylation, and chro-
matin remodeling. Working closely with epigenetic modifiers, miRs play an important role in inducing and
maintaining pluripotency. Future Directions: The dynamic changes in epigenetic marks during reprogramming
and their role in cell fate changes are being uncovered. This review focuses on these new advances in the
epigenetics of PS cells. Antioxid. Redox Signal. 17, 205–223.
Introduction
Embryonic stem (ES) cells, which develop from embry-onic inner cell mass during the stage of preimplantation,
can proliferate indefinitely maintaining their phenotype and
differentiate into any cell types of the three germ layers (41,
172), a characteristic known as pluripotency. These self-
renewing capabilities and pluripotency of ES cells are
mediated by several transcription factors: OCT4, SOX2, and
NANOG (17, 99), which are highly expressed in undifferen-
tiated ES cells (175, 180). Pluripotency-related transcription
factors co-occupy promoters of KLF4 and other genes that are
involved in self-renewal (17, 77, 99). These factors also bind to
the promoters of regulator genes of developmental lineage
commitment and cellular differentiation (17, 99) to inhibit the
expression in ES cells (‘‘silencing’’). In 2006, Takahashi and
Yamanaka discovered that overexpression of four transcrip-
tion factors, Oct3/4, Sox2, Klf4, and c-Myc, can reprogram
fibroblasts into ES-like cells, referred to as induced pluripo-
tent stem (iPS) cells. iPS cells closely resemble ES cells in
genomic, cell, and molecular biologic characteristics. Re-
markably, the same four factors identified in the murine
system were able to confer pluripotency in human cells, in-
dicating that the fundamental transcriptional network gov-
erning pluripotency is conserved across species. In contrast to
ES cells, direct reprogramming provides a convenient and
ethical means of generating pluripotent stem (PS) cells.Within
just a few years of their discovery, iPS cells have been shown
to hold incredible potential for research and therapeutic ap-
plications in regenerative medicine. Intriguingly, iPS cells
were found to have very similar genetic and epigenetic fea-
tures to ES cells. Gene regulation is affected not only by the
DNA sequence that carries heritable information, but also by
epigenetic modifications that alter DNA and the chromatin
proteins. Epigenetic modifications include histone modifica-
tions, DNA methylation, and nucleosome rearrangement.
Because gene regulation is influenced by epigenetic modifi-
cations, the stemness of PS cells, ES cells, and iPS cells can be
characterized by a unique epigenetic signature. Therefore,
exploring the epigenetic landscape of PS cells will be useful for
understanding their biologic characteristics and differentia-
tion and therapeutic potentials. This review focuses on the
role of epigenetic regulation in PS cells.
Key Factors of Epigenetic Regulation
As the substrate of transcription, chromatin is subjected to
various forms of epigenetic regulation, including histone
modifications, DNAmethylation, and chromatin remodeling.
Histone modifications
Histones, DNA-wrapping proteins, are subjected to post-
translational modifications including acetylation and meth-
ylation by enzymes primarily on their N-terminal tails for
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regulating chromatin structure. The core of histones H2A,
H2B, H3, and H4, which comprise high-order DNA structure
units called nucleosomes, can be modified by these post-
translational additions of chemical groups. Acetylation of
histones occurs at multiple lysine sites by the balanced actions
of histone acetyltransferase (HAT) and histone deacetylase
(HDAC), and the resultant acetylated lysine residues can in-
terfere with the positive charge of histones, resulting in
weakening the interaction with negatively charged DNAs
that can directly influence chromatin structure and fluidity
(Fig. 1A). Histone methylation is the modification of histone
proteins by the addition of mono- (me1), symmetrical di-
(me2s), and asymetrical di- (me2a) methyl groups at arginine
residues (Fig. 1B), and mono- (me1), di- (me2), and tri- (me3)
methyl groups at lysine residues (Fig. 1C). Unlike acetylation,
methylation is highly site-specific, and is maintained by his-
tone methyltransferase (HMT) and histone demethylase
(HDM) (Fig. 1B, C). Histone methylation is generally associ-
ated with repression of gene expression. For example, tri-
methylation of lysine 9 and lysine 27 of histone 3 (H3K9 and
H3K27) is correlated with inactive regions of chromatin.
However, methylation of lysine 4 of histone 3 (H3K4) or ar-
ginine on H3 and H4 result in transcriptional activation.
By regulating chromatin structure, epigenetic modifica-
tions play an essential role in controlling access to genes and
regulatory elements in the genome (20). The differences in
epigenetic status between a somatic cell and a PS cell are ev-
ident, and dedifferentiation requires global epigenetic repro-
gramming. For instance, PS cells contain bivalent domains
that are characteristic chromatin signatures (10, 11). These are
regions enriched for both repressive histone H3 lysine 27 tri-
methylation (H3K27me3) and active histone H3 lysine 4 tri-
methylation (H3K4me3) (116). It was assumed initially that
bivalent domains might be ES-cell specific because they were
first identified using chromatin-immunoprecipitation (ChIP)
followed by hybridization to microarrays (ChIP-Chip) that
featured key developmental regulators. All of these resolved
either to a univalent (H3K4me3 only or H3K27me3 only) state
or lost both marks in differentiated cells (10). Using ChIP
followed by high-throughput sequencing (ChIP-seq) tech-
nology, Mikkelsen and colleagues showed that bivalent do-
mains are more generally indicative of genes that remain in a
poised or balanced state characterizing their plasticity. Plur-
ipotent cells were found to contain large numbers of bivalent
domains (*2500) compared with multipotent neural pro-
genitor cells (NPCs) (*200) that still retain multilineage po-
tential but are more restricted than ES cells (109).
DNA methylation
A second component of the epigenetic marks is DNA
methylation, which is a stable and heritable mark that is in-
volved in gene silencing, including genomic imprinting and
X-chromosome inactivation. DNA methylation patterns are
dynamic during early embryonic development and are es-
sential for normal development (141). Overall DNA methyl-
ation levels remain stable during ES-cell differentiation,
although they are not static at any individual gene level (109).
The 5¢-promoter regions of many transcriptional units contain
clusters of the dinucleotide CpG, which are methylated at
transcriptionally silent genes and demethylated upon acti-
vation. In differentiated cells, the Oct4, Nanog, and Sox2 pro-
moter regions are highly methylated and in an inactivated
state, whereas in ES cells these promoters are unmethylated
and in an activated state. During reprogramming, almost
complete demethylation of these promoters has been
FIG. 1. Key factors of epigenetic regulation. (A) Histone acetylation. Histones are acetylated at amino groups on lysine
residues in N-terminal tail by HAT, with acetyl-CoA serving as the acetyl donor. Deacetylation of histones is mediated by
classical HDAC class I, II, and IV using hydrolysis of acetate from lysine residues, or sirtuins, HDAC class III, which remove
acetyl groups with NAD + releasing nicotinamide and the unique metabolite O-acetyl-ADP-ribose. lys, lysine; HAT, histone
acetyltransferase; HDAC, histone deacetylase; acetyl-CoA, acetyl coenzyme A; NAD + , nicotinamide adenine dinucleotide;
Nam, nicotinamide; OAADPr, 2¢-O-acetyl-ADP-ribose. (B) Histone arginine methylation. Arginine residues on histones can
be monomethylated by PRMTs using SAM as methyl donor, and can be catalyzed through serial addition of methyl groups
from SAM to ADMA by type I PRMT or SDMA by type II PRMT. HDM JMJD6 catalyzes the hydroxylation of methyl-
arginine residues by consumption of both 2-OG and O2, releasing succinate and CO2. arg, arginine; PRMT, protein arginine
methyltransferase; HDM, histone demethylase; SAM, S-adenosyl methionine; SAH, S-adenosyl homocysteine; 2-OG,
2-oxoglutarate; Succ, succinate; ADMA, asymmetric dimethyl-arg; SDMA, symmetric dimethyl-arg. (C) Histone lysine
methylation. Lysine can be mono-, di-, or tri-methylated by serial iteration of HKMT using SAM as a methyl donor.
Monomethyl and dimethyl-lysine can be hydroxylated by HDMs in a 2-OG-dependent manner ( JmjC proteins) or FAD-
dependent manner (LSD1). Trimethyl-lysine can be demethylated by JMJD6, which has arginine demethylase activity HKMT,
in a 2-OG-dependent manner. HKMT, histone lysine methyltransferase; FAD + , flavin adenine dinucleotide; jmjC, jumonji-
domain containing; LSD1, lysine-specific demethylase 1. (D) DNA methylation. A methyl group from SAM is attached to the
5th carbon from the nitrogen atom in the base of cytosine by DNMT resulting in 5-mC. 5-mC can be further hydroxylated by
TET family enzymes to form 5-hmC. Demethylation of 5-mC and 5-hmC base can be initiated by deamination through the
activity of AID followed by the BER pathway, which is the stepwise enzymatic mechanism for repairing damaged DNA
using DNA glycosylase, AP endonuclease, dRpase, DNA polymerase, and DNA ligase. BER, base excision repair; DNMT,
DNA methyltransferase; TET, ten–eleven translocation; dR5P, deoxyribose-5-phosphate; 5-mC, 5-methylcytosine; 5-hmC,
5-hydroxymethylcytosine; AID, activation-induced cytidine deaminase; AP, apurinic/apyrimidinic; dRpase, deoxyribo-
phosphodiesterase. (E) Chromatin remodeling proteins. The binding of the chromatin remodeling complex, SWI/SNF, ISWI,
and CHD, to chromatin is mediated by the unique domain (bromo, PHD bromo, and chromo) of each protein, which can
interact with specific modified histones (acetylated or methylated) and methylated DNA in an ATP-independent manner. The
steps of chromatin remodeling, including disruption of histone-DNA contacts, ejecting the nucleosome (ejection), and re-
positioning (sliding), are dependent on the hydrolysis of ATP. SWI/SNF and CHD family proteins can trigger ejection of the
nucleosome, while ISWI can slide a nucleosome to another position. SWI/SNF, switch/sucrose nonfermentable; ISWI,
imitation switch; CHD, chromodomain helicase DNA-binding.
<
206 HAN AND YOON
EPIGENETICS AND STEM CELLS 207
observed (102, 115, 121, 184). Therefore, the loss of DNA
methylation at the promoters of pluripotency-related genes
appears essential for achieving reprogramming to plur-
ipotency state. Interestingly, loss of DNA methylation at this
class of genes seems to be a rather late event in the repro-
gramming process because cells that have already acquired
self-renewing properties still showed high levels of DNA
methylation (115).
DNA methyltransferase (Dnmt)1, Dnmt3a, and Dnmt3b
are three enzymes necessary for DNA methylation (14, 53)
(Fig. 1D). Dnmt1 maintains DNA methylation at hemi-meth-
ylated DNA after DNA replication during cell divisions,
whereas Dnmt3a and Dnmt3b are responsible for establishing
de novo DNA methylation (28). Lack or mutation of Dnmt1
causes a two-third loss of DNA methylation or embryonic
lethality (96). Embryos deficient in Dnmt1 are smaller and
seem to have delays in developmental processes (96). Em-
bryos with mutant Dnmt3b seem to proceed normally in their
developmental stages initially but show multiple defects in
their later stages (126). In mouse embryonic fibroblasts
(MEFs), conditional deletion ofDnmt3b leads to partial loss of
methylation (38). These findings show that Dnmt1 and
Dnmt3b play a significant role in maintenance of proliferating
cells and their epigenomic landscape. In contrast, lack of
Dnmt3a does not seem to cause obvious developmental de-
fects. A study showed that homozygous Dnmt3a knockout
mice developed to term but died within*1 month after birth
(126). Dnmt3a seems to function as a co-regulator of Dnmt1
and Dnmt3b, and interacts with the N-terminus of histone
H3 (67, 127). It has been suggested that it functions as a co-
regulator of both Dnmt3a and Dnmt3b and has recently been
shown to interact with the N-terminal tail of histone H3 when
it lacks methylation at lysine 4 (67, 127).
Chromatin remodeling
Chromatin remodeling enzymes add or remove histone
covalent modifications and utilize the energy of ATP hydro-
lysis to disrupt chromatin structure. This makes DNA/chro-
matin available to proteins that need to access DNA or
histones directly during cellular processes. There are three
well-characterized families of ATP-dependent nucleosome
remodeling enzymes, SWI/SNF, ISWI, and chromodomain
helicase DNA-binding (CHD). These are multi-subunit com-
plexes containing a conserved ATPase domain as the catalytic
subunit, with additional components to form large multi-
protein-complexes, which promote specific histone post-
translational modifications and incorporation of histone
variants (75, 145) (Fig. 1E). The initial creation of the DNA
loop or bulge is the result of the translocase activity that has
been described to SWI/SNF and ISWI (143, 186, 200). The
ATPase of SWI/SNF binds to a specific location on the nu-
cleosome, from which it utilizes its 3¢ to 5¢ translocase activity
to drawDNA into one entry/exit and pump it to the other in a
directional wave (144). Binding of the complex to the nucle-
osome creates significant rearrangement of the DNA with
respect to the histone octamer even in the absence of ATP
hydrolysis, which may facilitate the creation of the DNA
bulge required for ATP-dependent translocation (101). In
contrast to SWI/SNF, the smaller ISWI chromatin remodeling
complexes make limited contacts with the nucleosome and
the extranucleosomal DNA (33, 48, 71, 149). These complexes
bind their substrate as a dimeric motor to facilitate the bidi-
rectional and processive translocation of DNA over the nu-
cleosome (15, 47, 133). This is consistent with the role of these
remodelers in nucleosome spacing, and their ability to sample
DNA linker lengths to position nucleosomes equidistant from
either end (48, 165, 195, 199). In this case, ATP hydrolysis by
one of the two ATPases results in loosened DNA-histone
contacts that may act similarly to the ATP-independent con-
formational change upon SWI/SNF binding to promote
DNA translocation following ATP hydrolysis by the second
ATPase (49). ATPases of the CHD family are characterized by
N-terminal tandem chromodomains in addition to the con-
served DEAD/H-related ATPase domain (132, 173). CHD
is targeted to sites of active transcription through PHD-
mediated recognition of H3K4me3 (45, 156), and associates
with other preinitiation factors to facilitate transcriptional
elongation and splicing (157). Despite the similarity between
their core enzymatic subunits, their common affinity for nu-
cleosomes, and their common ability to disrupt nucleosomal
templates in vitro, there is little functional similarity between
members in vivo and as a result, very little predictive power
for members of unknown function.
Epigenetic Landscape in Pluripotent Stem Cells
There are unique epigenetic marks in PS cells, ES cells, and
iPS cells. It is well known that certain epigenetic marks are
critical for maintaining pluripotency, which include histone
modifications, DNA methylation of pluripotency genes, and
regulation of pluripotency- or differentiation-specific micro-
RNA (miRs) expression. However, other studies still claim
that a majority of epigenetic marks are unnecessary for ES cell
survival. Although it is possible to maintain PS cells without
all of their epigenetic marks, this leads to a decrease in their
differentiation potential. Thus, the degree of in vitro epigenetic
influence in pluripotency of ES cells needs to be assessed by
further studies.
Chromatin structure in PS cells
PS cells, including ES and iPS cells, have a dynamic and
specialized higher order chromatin structure that is highly
organized for the regulation of gene expression programs
during development and differentiation, and is established by
histone modification, DNA methylation, and the activity of
ATP-dependent nucleosome remodeling complexes (107). PS
cells have distinctive chromosomal regions that contain the
genes that maintain pluripotency. A region of clustered
pluripotency genes, including NANOG at chromosome 12p,
has more central nuclear localization in ES cells than in dif-
ferentiated cells (187). Although the functional significance of
positioning in the nuclear center is unknown, the presence of
the nuclear spots within the most gene-dense human chro-
mosomes suggests that it may confer some transcriptional
advantage (19). Chromosome 12p contains other pluripotency-
related genes, STELLA and GDF3, which are also expressed in
ES cells and downregulated upon differentiation (31). An-
other pluripotency gene, OCT4, at chromosome 6p forms a
loop to relocalize to a position outside its chromosome terri-
tory (187). The data showing increased DNAmethylation and
histone deacetylation of the OCT4 enhancer/promoter in
trophoblast cells compared with ES cells are consistent with
a more long-range remodeling of chromatin architecture
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around OCT4, which might also contribute to its transcrip-
tional regulation (58). Preferential association of inactive
genes with the nuclear periphery has been reported in dif-
ferentiated cells; however, neither NANOG nor OCT4 is as-
sociated with the nuclear periphery of clusters of inactive
genes (198) (Fig. 2). In addition, genes and chromosome ac-
tivities are directly related to their spatial positioning within
the nucleus that is prone to alterations during early differen-
tiation (78, 104). Furthermore, studies have indicated that
nuclear structures such as nucleolus, heterochromatin (129),
nuclear speckles (domains enriched in splicing factors) (32),
and nuclear lamina experience morphological changes during
the early stage of differentiation.
Histone modification in PS cells
N-terminal tail residues of histones can undergo post-
translational modifications such as acetylation, methylation,
and phosphorylation (81). Given that ES and somatic cells
contain almost identical genomic DNA, epigenetic regulation
is one of the major influences on their pluripotency and dif-
ferentiation potential. To maintain pluripotency in ES cells,
differentiation-triggering genes should be inactive. Polycomb
group proteins (PcGs) play important roles in silencing these
developmental regulators. They form multiple polycomb re-
pressive complexes (PRCs), the components of which are
conserved from Drosophila to humans (148). The PcG proteins
function in two distinct PRCs, PRC1 and PRC2. Genome-wide
binding site analyses of PRC1 and PRC2 inmouse ES cells and
PRC2 in human ES cells (18, 93) showed that the genes reg-
ulated by the PcG proteins are co-occupied by nucleosomes
with trimethylated H3K27. These genes are transcriptionally
repressed in ES cells and are preferentially activated when
differentiation is induced. The pluripotency factors Oct4,
Sox2, and Nanog co-occupy a significant fraction of the PcG
protein-regulated genes when acting as transcription factors
(18, 93). Most of the transcriptionally silent developmental
regulators targeted by Oct4, Sox2, and Nanog are also occu-
pied by the PcGs (11, 18, 93). PRC2 catalyzes H3K27 meth-
ylation, an enzymatic activity required for PRC2-mediated
epigenetic gene silencing. H3K27 methylation is thought to
provide a binding surface for PRC1, which facilitates oligo-
merization, condensation of chromatin structure, and inhibi-
tion of chromatin remodeling activity in order to maintain
silencing. PRC1 also contains a histone ubiquitin ligase,
Ring1b, whose activity appears to contribute to silencing of
genes in ES cells (162). How the PcG is recruited to genes
encoding developmental regulators in ES cells is unknown.
Some of the most conserved vertebrate sequences are associ-
ated with genes encoding developmental regulators, and
some of these may be sites for DNA-binding proteins that
recruit PcG proteins (Fig. 3).
Recent studies demonstrated that the silent developmental
genes that are occupied by Oct4, Sox2, Nanog, and PcG pro-
teins experience an unusual form of transcriptional regulation
(55). These genes undergo transcription initiation but not
productive transcript elongation in ES cells. The transcription
initiation apparatus is recruited to developmental gene pro-
moters, but RNApolymerase is incapable of fully transcribing
these genes, presumably because of repression mediated by
the PcG. This explains why the silent genes encoding devel-
opmental regulators are generally organized in bivalent do-
mains that are occupied by nucleosomes with histone
H3K4me3 and H3K27me3 (4, 11, 55).
The presence of inactive RNA polymerase at the promoters
of genes encoding developmental regulators may explain
why these genes are especially poised for transcription acti-
vation during differentiation (18, 93). PcG complexes and
associated proteins may serve to pause RNA polymerase
machinery at key regulators of development in PS cells and
lineage-committed cells where they are not expressed. When
the cells are activated, PcGs and nucleosomes with H3K27
methylation are lost (18, 93, 116), allowing the transcription
apparatus to fully function and transcribe these genes. The
mechanisms that lead to selective activation of genes encod-
ing specific developmental regulators are not yet understood
(87). Beyond the specific regulation of development-related
genes, ES cells maintain chromatin in a highly dynamic and
transcriptionally permissive state. Fewer heterochromatin
foci are detected in ES cell nuclei compared with differenti-
ated cells. Fluorescence recovery after photobleaching and
biochemical analyses reveal that ES cells, compared with
differentiated cells, have an increased fraction of loosely
bound or soluble architectural chromatin proteins, including
core and linker histones and heterochromatin protein HP1. A
hyperdynamic chromatin structure is functionally important
for pluripotency (113). The status of histone modifications
FIG. 2. Chromatin structures in pluripotent stem cells.
The nucleus of the cell is composed of a nuclear envelope
that contains pores, a meshwork of intermediate filaments
(nuclear lamina), nucleolus, subnuclear bodies including
nuclear speckle, which is enriched in pre-mRNA splicing
factors, and distinct territories of each chromosome that oc-
cupy a defined volume of the nucleus. Chromosome 12p
(green) including NANOG, which is located well within the
12p chromosome territory, has a more central nuclear local-
ization in ES cells, while chromosome 6p (dark green) with
OCT4 (orange), which forms a loop to relocalize to a position
outside the 6p chromosome territory, is located at an inter-
mediate position between the nuclear periphery and center.
(To see this illustration in color the reader is referred to the
web version of this article at www.liebertonline.com/ars).
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also indicates that the chromatin in ES cells is more tran-
scriptionally permissive than in differentiated cells. Con-
sistent with the global dynamics of chromatin, ES cell
differentiation is associated with a decrease in global levels of
active histone marks, such as acetylated histone H3 and H4,
and an increase in repressive histone marks, histone H3 lysine
9 methylation (91, 113). Taken together, these unique epige-
netic characteristics of ES cells facilitate rapid but regulated
transcription, allowing differentiation down different cell fate
pathways as needed by the organism.
Several studies of murine iPS cells have identified a small
number of representative loci that have consistent chromatin
and DNA methylation patterns (102, 170, 184). A ChIP-Chip
study investigating H3K4me3 and H3K27me3 in the pro-
moter regions of 16500 genes showed that iPS cells were
highly similar to ES cells in epigenetic state (102). The
H3K4me3 pattern was similar across all samples, indicating
that reprogramming was largely associated with changes in
H3K27me3 rather than H3K4me3 (102). Another ChIP-Seq
study exploring genome-wide chromatin maps in several iPS
lines derived by different methods (110, 184) demonstrated
that global levels of repressive H3K27me3 and the charac-
teristic bivalent chromatin structure are retained in the vari-
ous iPS cell lines. The restoration of repressive chromatin
marks appears crucial to stably silence lineage-specific genes
that are active in somatic cells and inactive in pluripotent
cells, suggesting that failure to establish the repressive marks
results in incompletely reprogrammed cells. Activating
H3K4me3 patterns are also crucial for complete reprogram-
ming and have been observed to be restored genome wide, in
particular around the promoters of pluripotency-associated
genes such as Oct4 and Nanog, in the fully reprogrammed iPS
lines (115).
Histone demethylation plays a critical role in ES cell epi-
genesis and pluripotency. The mechanism of histone de-
methylation was discovered only recently (81, 150, 151).
Removal of a specific H3K27 tri-methylation can be achieved
by two enzyme families: Jumonji ( JMJD) and UTX (1, 35, 92).
Jmjd1a and Jmjd2c genes, which are responsible for H3K9me2
and H3K9me3 demethylation, are up-regulated by Oct4.
Jmjd2a induces Nanog up-regulation and Jmjd1a demethy-
lates H3K9me2 at the Tc11, Zfp57, and Tcfcp211 promoters
(100) (Fig. 1C).
Histone acetylation activates transcription. The HAT p300
regulates the state of pluripotency by activating transcription.
p300 is recruited to sites of multiple pluripotency factors such
asNanog,Oct4, and Sox2 (27). These multiple binding sites are
involved in activation of the H3K4me3 mark. In ES cells,
Tip60-p400 is the HAT and chromatin remodeling complex
that positively or negatively regulates gene expression and
DNA repair (146, 160). The complex is also a transcriptional
activator that incorporates the histone H2AZ and catalyzes
histone acetylation at target promoters (160). ES cells with
Tip60-p400 deficiency show abnormal morphology and can-
not self-renew or differentiate. There are significant similari-
ties between genes affected by Tip60-p400 depletion and
Nanog depletion. Furthermore, Tip60-p400 binding, Nanog
binding, and the H3K4me3 mark have strong correlations
with one another. Tip60-p400 localizes to both highly ex-
pressed genes and poised genes marked by bivalent modifi-
cations (43). Tip60-p400 binding is necessary in regulating
histone H4 acetylation. In ES cells, Tip60-p400 can act as a
repressor by catalyzing histone acetylation.
Histone deacetylation is mediated by nucleosome re-
modeling deacetylase (NuRD) complexes, which are respon-
sible for HDAC activities as well as ATP-dependent
chromatin remodeling. The NuRD complex consists of SNF2-
like ATPase subunits, Mi2a or -b, deacetylase subunits
HDAC1/2, and associated subunits including methyl-CpG-
binding proteins MBD 1/2/3 and metastasis associated pro-
teins MTA1/2/3 (37). Mi2b, in association with HDACs and
MBD subunits, plays an important role as a transcriptional
repressor but can also be an activator and is required for he-
matopoietic stem cell self-renewal and differentiation (179,
189, 196). Pluripotency requires MBD3, as ES cells without
MBD3 cannot commit to specific developmental lineages (72).
FIG. 3. Epigenetic status of
pluripotent stem cells. Plur-
ipotent stem cells have ap-
propriate epigenetic marks
for different genes. Master
regulators for pluripotency-
related genes are highly acti-
vated in PS cells by an open
chromatin structure consisting
of an unmethylated promoter
region (small white circles on
DNA strands), acetylated his-
tones (Ac) that are mediated
by the regulation of HATs and
HDACs, and H3K4 methyla-
tion (K4). The open chromatin structure for active promoter regions is also remodeled byATP-dependent CRPs, andpermissible
for binding of TFs to recruit RNApolymerase for transcription of genes. The bivalent domains at the promoters of early response
genes to differentiation, consisting of both repressive H3K27 methylation (K27) and active K4 marks, keep them poised for
activation in pluripotent stem (PS) cells with the binding of PcG proteins long-term silencing of differentiation-related genes
through DNA methylation are performed by DNMTs. DNA methylation (small black circles on DNA strands) is often accom-
panied by the repressive H3K9 methylation (K9), on promoters, which is mediated by HMTs and leads to chromatin
compaction. DNA methylated-silenced promoters show a loss of H3K4 methylation and histone de-acetylation. CRPs, chro-
matin remodeling proteins; TFs, transcription factors; Ac, acetylation; K4, H3K4 methylation; K27, H3K27 methylation; PcG,
polycomb group protein; HMTs, histone methyltransferases; K9, H3K9 methylation.
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However, MBD3 is not required for expression of plur-
ipotency factors but only for repression of gene transcription.
Unrepressed promoters become hyperacetylated at H3K9 and
H4, whereas there is no change in the acetylation status of
other inactive promoters, suggesting that the NuRD complex
is not globally required for ES cell gene silencing. Further-
more, MBD3-depleted ES cells can undergo initial stages of
differentiation by forming embryoid bodies and trophecto-
derm but fail to differentiate further except when induced
with retinoic acid. MBD3-depleted ES cells also fail to develop
in utero as chimeric embryos when aggregated with wild-type
morulae. Thus, MBD3 as part of the NuRD complex facilitates
ES cell differentiation but is not absolutely required for ES
cells to respond to all inductive signals.
DNA methylation in PS cells
DNA methylation suppresses gene expression; thus, in ES
cell status, most of the pluripotency-related transcription
factors are hypomethylated and lineage-committed genes
are heavily methylated at their promoter regions (Fig. 3).
H3K4me3 and DNA methylation are known to be linked.
DNA methylation maps have been created for mouse and
human pluripotent cells (89, 97, 109). High-CpG promoters of
ES cells have H3K4me3 histone modifications and entirely
lack DNA methylation (109,116). This may be related to the
ability ofDnmt3 to bind to unmodifiedH3K4 (127). In ES cells,
CpGs in low-CpG promoters, which are generally associated
with tissue-specific genes (183), are mostly methylated, with
the exception of a small subset (< 10%) that are enriched for
H3K4me3 or H3K4me2 (109). All pluripotency genes in ES
cells have H3K4 methylation and DNA hypomethylation (65,
115, 116). However, the loci that are devoid of H3K4 and
H3K27 methylation show extensive DNA methylation in-
stead (46). Genome-wide bisulfite sequencing in human ES
cells (89, 97) has confirmed the findings of these previous,
more limited mouse (46, 109, 118) and human studies (183).
The Dnmt family maintains and directs catalysis of DNA
methylation. The methyl-CpG-binding domain (MBD) family
recognizes DNA sequences with high CpG content and
mediates the effects of DNA methylation (60). During the
division of the zygote, paternal and maternal methylation
patterns disintegrate by down-regulating the expression of
the Dnmt1 gene (136). During embryogenesis and formation
of germ layers, there is a re-establishment of a new DNA
methylation pattern. During this period, the epigenomic
status of ES cells inside ICM is restored to redefine plur-
ipotency. Studies of Dnmt1-deficient (Dnmt1 -/- ) and
Dnmt3a/Dnmt3b-deficient (Dnmt[3a -/ - ,3b-/ - ]) ES cells
have demonstrated that restoring DNA methylation is es-
sential for development (94, 126). TheseDnmtmutant ES cells
exhibited an early-lethal phenotype, defects in differentiation
during embryoid body formation of Dnmt1 -/- (128), and
teratoma formation of late-passage Dnmt[3a -/ - ,3b-/- ] (29).
Down-regulation of Oct4 and Nanog expression during the
differentiation of NT2 cells, a neuronally committed human
teratocarcinoma cell line, is related to methylation of
5¢-flanking regions of both these genes (36).
While the role of non–CpG methylation is unclear in so-
matic cells, recent evidence suggests that the role of non–CpG
methylation is important in maintenance of ES cell plur-
ipotency. In adult somatic tissues, DNAmethylation typically
occurs at the site of the CpG dinucleotide. However, non–
CpG methylation, including CpA and CpT methylation, is
prevalent in mouse ES cells (108, 109) and human ES cells (89,
97). Non–CpG methylation level is mediated by Dnmt3a and
Dnmt3b (39). Overexpression of Dnmt3a in Drosophila, which
has no Dnmts or DNA methylation (53), induces CpG as well
as non–CpG methylation. These data support the notion that
non–CpG methylation results from de novo methylation ac-
tivity of Dnmt3a, which is highly expressed in ES cells and
poorly expressed in somatic tissues (135). In both mouse and
human, non–CpG methylation is low in differentiated cells
(97, 135) and reappears in iPS cell generation (97).
Recent studies have shown the importance of DNA hy-
droxymethylation in regulating gene expression. In fact,
DNA hydroxymethylation is highly prevalent in ES cells
compared with somatic cells. The ten–eleven translocation
(TET) family direct catalysis of 5-methyl cytosine to 5-
hydroxymethylcytosine (5hmC) (168) (Fig. 1D). 5hmC is
detectable in undifferentiated mouse ES cells as well as in
Purkinje neurons and granule cells (82). During the differen-
tiation of ES cells, the amount of Tet1 and 5hmC decreases
(168), and Tet1 knockdown by shRNA damages ES cells’
ability to maintain and self-renew with diminishing Nanog
expression, suggesting a crucial role of Tet1 in maintaining
pluripotency (66). However, a more recent study showed that
Tet1-deficient (Tet1-/- ) mouse ES cells still maintain plur-
ipotency with expression of pluripotency markers Oct4, Sox2,
and Nanog, and can drive normal embryo development in
tetraploid complementation assays, although these mutant
mice have a partial reduction of 5hmC and a slightly small
body size at birth (34). Another study using shRNAs to
knock down Tet1 and Tet2 also showed that depletion of these
genes did not affect Nanog expression, self-renewal, or plur-
ipotency (80).
Chromatin remodeling enzymes
ES cells are rich in euchromatin and diffused heterochro-
matin. Chromatin structural remodeling leads to highly
compact heterochromatin during differentiation. The change
from lower to a higher chromatin structure state is helped
by chromatin remodeling protein complexes. Either the re-
modeling enzymes have the ability to alter the N-terminal
characteristics of histones by adding or removing acetyl,
methyl, ubiquitin, and sumo groups, or the remodeling pro-
teins are composed of ATP-dependent enzymes, which use
energy to transiently separate the association between DNA
and histones. These modifications, in turn, may induce a
conformational change in nucleosome and chromatin con-
densation state. This kind of ATP-mediated remodeling pro-
vides an accessible DNA, which is more prone to gene
activation or repression by the transcriptional apparatus (154)
(Fig. 3). An example is the SWI/SNF protein complex in
mammals, which is composed of several different subunits
such as Snf2. Different chromatin remodeling enzymes that
are ATP-dependent are highly expressed in mouse ES cells
and are down-regulated after leukemia inhibitory factor re-
moval (84). Mice that lack remodeling proteins SNF2H (163),
BRG1 (21), SNF5 (79), or SSRP (24) die before implantation.
The SWI/SNF mechanism of catalysis and regulation of ES
cell pluripotency is not very well understood and requires
further investigation. It has been found that the SWI/SNF
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chromatin remodeling component, BAF250, is vital for ES cell
pluripotency (50). BAF250b dysfunction lowers expression of
pluripotency factors and increases that of lineage markers
such as Gata2. The SWI/SNF complex also regulates nucleo-
some sliding and eviction (56, 95).
miRs in PS cells
The function of miRs in stem cells has been established in
many systems, where disruption of Dicer or DGCR8, which
are miR-processing enzymes, leads to defects in embryo de-
velopment (12, 57, 73, 120, 123, 182, 188). Dicer-null mouse is
embryonic lethal, indicating its critical role in early embryonic
development (12). However, Dicer-null mouse ES cells are
viable but show defective cell cycle progression. Dicer-null ES
cells are defective in differentiation and fail to express dif-
ferentiation markers such as HNF4a, BMP4, and GATA1 (73).
Dicer-deficient cells further show decreased levels of DNA
methylation and Dnmts (9, 158) and increases in telomerase
recombination and elongation (9). This defect in DNA meth-
ylation leads to lack of differentiation by incomplete and re-
versible silencing of Oct4 (9, 158). DGCR8 knock-out mouse
ES cells show phenotypes similar to Dicer-deficient mouse ES
cells, showing reduced cell proliferation, abnormal cell cycle
control, and defects in differentiation (182). DGCR8-null ES
cells arrest in G1 phase and do not differentiate into teratoma,
a feature characteristic of normal ES cells (16, 76, 112). Blelloch
and colleagues have discovered specific functions for families
of miRs controlling cell cycle and self-renewal in DGCR8-null
mouse ES cells (111, 181) (Fig. 4).
ES cells have been reported to express a small subset of
unique miRs (23, 62, 86, 119, 166). The humanmiR-371 cluster
is located on chromosome 19 and is analogous to the mouse
miR-290 cluster, and the miR-302 cluster located on chromo-
some 4 is associatedwith bothmurine and human ES cells (62,
164, 166). Two additional clusters, miR-17 on chromosome 13
and the miR-106a cluster on chromosome X, have also been
shown to be upregulated in ES cells (90).
miR-290 and miR-371 clusters. The miR-290 cluster is
comprised of six miRs (miR-290 to miR-295), all of which are
expressed at high levels in undifferentiated mouse ES cells but
decreasing upon differentiation (62). Exogenous miR-290 family
members can partially rescue self-renewal of Dicer-null cells (9,
158). The human homolog of the miR-290 cluster includes miR-
371, -372, -373, and -373*. These miRs were identified as em-
bryonic carcinoma and ES cell-specific miRs (69, 86, 166). The
cluster is transcribed as a single polycistronic transcript and
regulated by a common promoter (166). Mouse mutants with a
homozygous deletion of the miR-290–295 cluster are embryonic
lethal, demonstrating its importance during embryo develop-
ment (2). The ES core transcriptional regulatory circuit, Oct4,
Sox2, and Nanog, has recently been shown to be physically as-
sociated with promoters for the miR-290 cluster (105).
miR-302-367 cluster. Another ES cell-specific miRs clus-
ter is the miR-302–367 cluster, shown to be highly and spe-
cifically expressed in undifferentiated ES cell (69, 86, 119).
This cluster, encoded by human chromosome 4, consists
of nine different miRs: miR-302a, -302a*, -302b, -302b*, -302c,
-302c*, -302d, -367, and -367* (88). The ES cell-specific tran-
scription factors, Oct4, Nanog, Sox2, and Rex1, were shown to
be upstream regulators of the miR-302–367 promoter (8, 25).
In addition, miR-302–367 has been identified to post-
transcriptionally regulate cyclin D1 and Cdk4, affecting cell
cycle progression (25). In addition to their role in self-renewal
and proliferation, miR-302–367 may indirectly induce the
TGFb/Nodal/Activin pathway via inhibition of intermediate
negative regulators to maintain cells in the undifferentiated
state (7).
miR-17–92 cluster. The miR-17–92 cluster is highly
expressed in ES cells, and a single polycistronic transcript
generates six miRs: miR-17, -18a, -19a, -20a, -19b-1, and
-92a-1 (54, 62, 119). This cluster is a known OncomiR that
promotes cell proliferation in several forms of cancer (59, 85,
124, 137, 176) and is activated by c-Myc, a repressor of other
miRs such as miR-15 and let-7 (26). miR-20a is thought to play
a role in cell proliferation and inhibition of apoptosis at the G1
to S transition via a feedback loop with E2F factors (124, 167,
174, 191). The role of c-Myc in combination with Oct4, Sox2,
and Klf4 in inducing somatic cells to iPS cells suggests that
these miRs play a key role in stem cell renewal and plur-
ipotency. Indeed, Melton and colleagues demonstrated that a
let-7 inhibitor was able to replace exogenous c-Myc in the
production of iPS cell cultures (111).
let-7 family. ES cells are characterized by the presence of
low levels of let-7, which is highly expressed in differentiating
cell types (54, 86). Let-7g levels have been shown to be regu-
lated by LIN28, a gene highly expressed in pluripotent cells
(177). The LIN28 gene is in turn targeted by let-7 via target sites
in its 3¢-UTR (122, 130, 142, 177). Both LIN28 and let-7g genes
are associated with Oct4/Sox2/Nanog/Tcf3 binding in ES
cells, resulting in a regulatory loop where the core pluripotent
FIG. 4. microRNAs in pluripotent stem cells. microRNAs
(miRs) regulate both self-renewal and differentiation path-
ways of PS cells by regulating various factors that mediate
these processes. PS cell-specific miRs inhibit the transcriptional
repressors that target pluripotency-related genes, including
OCT4, NANOG, SOX2, KLF4, and MYC, or cell cycle-related
genes to promote self-renewal, and directly inhibit the ex-
pression of differentiation-related genes. Another mechanism
of promoting self-renewal is the regulation of let-7 miR pro-
cessing by LIN28, which directly binds to a consensus se-
quence in the pre-let-7 miR loop region. Positive and negative
regulations are shown by arrows and T lines, respectively.
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transcription factors activate the LIN28 gene associated with
maintenance of self-renewal and pluripotency while repres-
sing let-7g to prevent differentiation (105). Exogenous addi-
tion of let-7 miRs can suppress self-renewal in DGCR8 null
mouse ES cells but not in wild-type ES cells, and this sup-
pression can be inhibited by introduction of ES cell–cell cycle-
regulating miRs such as miR-294 (111).
Epigenetic Changes During Differentiation
The investigation of lineage specification and global epi-
genetic remodeling for specific cell types in vivo is a difficult
challenge despite advances in experimental technologies.
Therefore, PS cells have emerged as a powerful system to
investigate epigenetic changes during differentiation. As hu-
man PS cells are the only available model system to study the
mechanism of differentiation and cell fate decision in human
developmental biology, they have been widely used for such
purposes. Most of genome-wide DNA methylation and his-
tone-modification studies were conducted comparing epige-
netic changes during differentiation of PS cells into their
differentiated lineages. During this cell fate change, PS cells
lose their pluripotency by silencing pluripotency-related
genes and gain differentiated cell phenotype by activating
silenced or poised lineage-specific genes as the promoters and
enhancers of these genes become accessible by epigenetic
changes. The promoter-specific regulation of chromatin
structure by specific enzymes leads to proper differentiation
into specific cell types. However, the mechanism of recruiting
enzymes that regulate chromatin remodeling and histone
modification needs to be further elucidated.
Neural differentiation
During the differentiation of PS cells into the neural lineage,
the promoters of many genes related to the neural lineage,
including Nestin, Otx2, Nkx2-2, Astn, Olig1, and the miRNA
mir-9-3, lose a repression mark, H3K27me3, and retain a
monovalent activation mark, H3K4me3, resulting in trigger-
ing expression of these genes (116). This removal of
H3K27me3 is mediated by upregulation of H3K27-specific
HDM, Kdm6b (also known as Jmjd3), with downregulation of
specific HMT, enhancer of zeste homolog 2 (Ezh2) at the
promoters of neural genes (22). During the transition from
human ES cells to NPCs, pluripotency-related genes such as
NANOG, TERT, and LIN28, and non-neuronal lineage genes,
includingGATA4 andNODAL, gain another repressive mark,
H3K9me2, concomitantly with the loss of H3K4me3, leading
to their long-term repression (52). The transcriptional re-
pressor RE1-silencing transcription factor (REST, also known
as NRSF) targets a group of neuronal genes through its in-
teraction with the 21-base pair RE1 element. It represses
neuronal differentiation by recruiting histone modifiers and
chromatin-binding proteins (5). A subset of REST target genes
escape the repression and are selectively induced during
the transition from ES cells to NPCs. Degradation of REST by
b-transducin repeat-containing protein 1 (b-TRCP1) has been
shown to be essential for ES cell commitment to a neural fate
(185). Also, DNAs at the loci of neural-related distal regula-
tory elements is demethylated at CpG site upon commitment
to the neural lineage, whereas non-neural gene loci gain CpG
methylation in NPCs (118). The targeting mechanism of his-
tone modifiers and DNMTs to specific loci is not well un-
derstood. However, it has been shown that PcG proteins
preferentially target highly conserved promoters with long
unmethylated CpG islands in ES cells (138, 147).
Endothelial differentiation
The role of histone acetylation in endothelial differentiation
was identified by the studies using small molecule HDAC
inhibitors such as trichostatin A (TSA). These inhibitors block
the endothelial differentiation of adult progenitor cells by
downregulation of HOXA9 expression (140). Other studies
also showed similar negative effects of TSA or valproic acid
(VPA), another HDAC inhibitor, on the expression of endo-
thelial nitric oxide synthase (eNOS) at a high concentration
(*0.3 lg/ml) of inhibitors and on angiogenesis of human
endothelial cells (114, 139). In contrast, HDAC inhibitors at a
low concentration (0.1 lg/ml) in combination with DNMT
inhibitor, 5¢-aza-2¢-deoxycystidine (5-aza-dC), induced dif-
ferentiation into endothelial cells from bone-marrow-derived
multipotent adult progenitor cells (103). This inhibitor of
DNMT, 5-aza-dC, can also induce endothelial cell differenti-
ation frommouse ES cells (6). Interestingly, nitric oxide (NO),
which is generated by eNOS, results in the activation of class
IIa HDACs and subsequently induces mesoderm differentia-
tion of mouse ES cells (159). The elevated level of NO in en-
dothelial cells by shear stress and direct exposure of mouse ES
cells to NO upregulated vascular gene expression, including
Acta2 (also known as smooth muscle actin), Taglin (smooth
muscle protein 22-alpha), Pecam1 (CD31), Kdr (Flk-1), Mef2c,
and Acta1 (alpha-sarcomeric actin) (64, 159).
Cardiac differentiation
Inhibition of DNAmethylation by small molecule chemical,
5-aza-dC, also promotes cardiac differentiation of ES cells in a
time-dependent manner (193). In addition, inhibition of HDAC
by TSA promotes cardiac differentiation by increased expres-
sion of acetylatedGata4,Nkx2-5, andMef2c (74). In Nxk2.5-GFP
mouse ES cells, TSA exposure between days 7 and 8 of differ-
entiation doubled the percentage of GFP+ cells, and boosted
expression of Nkx2-5, Myh7 (b-MHC), and Naap (atrial natri-
uretic factor [ANF]). TSA-treated mouse EBs, which showed
enhanced acetylation of histone 3 and 4, have increasedGATA4
acetylation and DNA binding to the ANF promoter and en-
hancedcardiomyocyte differentiation (74). Another cardiac
differentiation-related histone methylatransferase is Dot1L,
which catalyzes H3K79 methylation despite lacking a SET do-
main (44).Dot1L knockoutmice are embryonically lethal due to
dilated heart and angiogenesis defects in yolk sac. ES cells from
Dot1L knockout blastocysts show global loss of H3K79 meth-
ylation aswell as other repressive histonemarks,H3K9me2 and
H4K20me3, and display aneuploidy, telomere elongation, and
proliferation defects (68). In addition, overexpression of cardiac-
enriched subunit of the SWI/SNF-like chromatin remodeling
BAF complex,Baf60c (also known as Smarcd3), when combined
with ectopic expression of Gata4 and Tbx5, was able to induce
cardiac differentiation of mouse embryos (171).
Reprogramming of Cell Fate and the Role
of the Epigenome
In 2006, Shinya Yamanaka discovered that adult somatic
cells can be reprogrammed to ES-like cells called ‘‘iPS cells’’
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using viral transduction of pluripotency-related transcription
factor genes (169, 170). The mechanism by which ectopic
transcription factors override the existing epigenetic state and
change it into a specific alternative state without passing
through normal development or complete resetting of all
marks is still largely unknown; however this triumph sug-
gests the flexibility of the epigenome and its influence on cell
fate determination. The key factors involved in the epigenetic
remodeling have not been identified, and many questions
regarding the dynamics of this process still remain.
Epigenetic changes during reprogramming
The term ‘‘epigenetics’’ was first coined by Waddington in
1942 to describe the role of genetic interactions in phenotype.
Later, he presented the epigenetic landscape model in 1957 by
using the metaphor of a ball traveling down a canal that starts
from the stage of the fertilized totipotent embryo and ends
with various lineage-specific cells. In this concept, cells move
downward through different one-way branched valleys in-
side a canal and select their ultimate irreversible cellular fates
(178). The four transcription factors essential in reprogram-
ming reverse the cells’ path in this canal by unlocking specific
epigenetic gateways, which normally induces stabilization
into a differentiated form (194) (Fig. 5).
Yamanaka proposed a stochastic model for iPS cell gener-
ation. A group of cells are prevented frommoving back up the
slope toward the state of pluripotency by some epigenetic
barrier; once they overcome such barriers, they will achieve
the ability to self-renew. The second group goes through
partial reprogramming. This will cause them to lose their
pluripotency and roll toward a specific lineage. The third
group with improper expression of ectopic factors trans-
differentiates. The fourth group undergoes apoptosis or death
instead of traveling on the slope. Due to large differences in
epigenetic status between ES cells and their differentiated
progeny, Oct4 and Sox2 cannot find their targets in somatic
cells. It has been proposed that c-Myc and Klf4 alter the
structure of chromatin, enabling these two core factors access
to their targets, thereby increasing the expression of down-
stream genes (170). c-Myc induces up-regulation of Gcn5
(histone acetyl transferase gene), which is a key player in
histone structure, and therefore might improve the accessi-
bility of target genes to Oct4. Klf4 is also acetylated by p300
(acetyl transferase protein) and has the ability to control gene
transcription through regulation of histone acetylation (42).
Histone modification during reprogramming
Studies using cDNA microarray and ChIP approaches re-
vealed that Oct4 regulates the expression of over 350 genes
in ES cells, including several epigenetic modifiers (106).
Two HDMs, Jmjd1a and Jmjd2c, have been identified to be
part of the groups of the genes regulated by Oct4 (100), and
Jmdj2c is recruited to the Nanog promoter. In this way, ES cell
transcription factors regulate the expression of chromatin
remodeling genes and, in turn, help unveil chromatin con-
formation in promoter regions of target genes allowing
self-regulation of the epigenetic network. During the repro-
gramming of fibroblasts into pluripotent cells, genes in an
open chromatin state, which is marked by H3K4me3 or
H3K4me3 and H3K27me3 (bivalent), are efficiently re-
activated, whereas genes that are silenced byH3K27me3 alone
remain mostly repressed. In both near promoters and inter-
genic regions, most of the high CpG promoters are enriched
with monovalent H3K4me3 (activation mark) or bivalent
H3K4me3 andH3K27me3 (repressionmark) in ES cells (Fig. 6).
However, MEFs show only H3K27 (115). One group of genes
shows the reactivation and associated gain of H3K4me3 at key
pluripotency factors. These can be further subdivided into two
classes: the first includes genes such as Lin28, Sox2, and Fgf4,
which are repressed by H3K27 and lack detectable H3K4me3;
the second includes the genes Oct4, Nanog, and Dppa, which
are repressed by DNA methylation and also lack detectable
FIG. 5. Epigenetic changes
in pluripotent stem cells and
reprogramming. Epigenetic
landscape of PS cells showing
cell populations with differ-
ent developmental potentials
is illustrated as marbles roll-
ing down a landscape into
one of levels at each cell fates.
At each developmental stage,
the combinations of changing
of epigenetic marks for dif-
ferent sets of genes determine
the epigenetic landscape of
cells. Thick arrows show ex-
amples of reprogramming
processes. (To see this illus-
tration in color the reader is
referred to the web version
of this article at www
.liebertonline.com/ars).
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H3K4me3. The other major group describes genes, including
MyoD, which are repressed byH3K27me3 and highly enriched
for developmental transcription factors. To create a truly plu-
ripotent cell line, these loci must remain repressed but need to
acquire H3K4me3 to reestablish their bivalency and thus their
developmental competence for all germ layers and cell types
(115).
DNA methylation during reprogramming
The efficiency of iPS cell reprogramming is extremely low
(0.01–0.1%) (61). Treating differentiated cells with DNA
methylation inhibitor 5-Aza-CR or siRNA or shRNA against
Dnmt1 to revert repressive epigenetic marks of pluripotency
genes can significantly increase the efficiency of iPS genera-
tion (115). These data suggest that epigenetic modifications
are acquired to overcome the epigenetic repression of one or
more key loci during the artificial process of reprogramming.
DNA methylation is a critical epigenetic barrier to cellular
reprogramming, and the removal of DNA methylation (i.e.,
demethylation) at the promoter of pluripotency genes is the
key mechanism of reprogramming (155) (Fig. 6). The molec-
ular mechanisms of DNA demethylation have been proposed
as passive or active processes. Passive DNA demethylation
occurs by DNA replication in the absence of methylation of
newly synthesized DNA strands when maintenance methyl-
ation is impaired (197). Active DNA demethylation depends
on demethylating enzymes, which is independent of replica-
tion (197). Activation-induced cytidine deaminase (AID, also
known as AICDA) is the only enzyme that has been proposed
as a DNA demethylase in mammalian reprogramming (13,
131). It is suggested that AID-mediated DNA demethylation
occurs due to deamination of methylated cytidine residues in
single-strandedDNA, followed byDNA repair (134). A recent
study using a cell fusion reprogramming strategy showed
that a rapid increase in Oct4 and Nanog expression was ac-
companied by DNA demethylation at their promoters (13).
Moreover, AID knockdown by siRNA decreases the expres-
sion of pluripotency genes such as Oct4 and Nanog by re-
ducing DNA demethylation (13). These data support the
importance of active DNA demethylation by AID in repro-
gramming.
Role of miRs in reprogramming
The importance of miRs for ES cells is further indicated by
the discovery that specific miRs mimics and inhibitors induce
the reprogramming of somatic cells into iPS cells (3, 70, 117).
Several miRs, including ES cell-specific cell cycle-regulating
(ESCC) miRs (miR-291a-3p, miR-291b-3p, miR-294, miR-295,
and miR-302), Myc-induced miRs (miR-200, miR-141, miR-
429, and miR-17-92 clusters), miR-92b, and the miR-520
cluster, have been shown to positively regulate the self-
renewal and pluripotency of ES cells. Among these, ESCC
miRs (miR-291-3p, miR-294, and miR-295) increase the effi-
ciency of reprogramming of fibroblasts into iPS cells induced
by Oct4, Sox2, and Klf4 (70). Additionally, the inhibition
of tissue-specific miRs, let-7, has been shown to promote
FIG. 6. Reprogramming of cell fate by epigenetic changes. The reprogramming factors OCT4, SOX2, and KLF4 bind
promoter regions of pluripotency-related genes, which is repressed by let-7 miRs in differentiated somatic cells, together with
other transcription factors, including NANOG, and recruit co-activators, such as the HAT, p300, during reprogramming. This
binding pattern is found in transcriptionally active genes in ES cells as open euchromatin structure with histone Ac, K4, and
unmethylated DNA (small white circles). In reprogrammed iPS cells, genes that are bound by OCT4 and inhibited by ESCC
miRs are often repressed potentially through the recruitment of PcG proteins, HDACs, or DNMTs (resulting DNA meth-
ylation as shown with small black circles), but become activated upon differentiation. ESCC, embryonic stem cell-specific cell
cycle regulating; iPS, induced pluripotent stem. (To see this illustration in color the reader is referred to the web version of
this article at www.liebertonline.com/ars).
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reprogramming (111). miR-125, which inhibits the expression
of Lin28, is also expected to positively influence reprogram-
ming (190, 192) (Fig. 4). More importantly, ectopic expression
of only miRs (miR-302/367 and miR-200c/302/369) without
transcription factor over-expression was shown to have suf-
ficient capability for rapid and efficient reprogramming of
mouse and human somatic cells into iPS cells (3, 117).
The equivalency of ES cells and iPS cells is controversial,
and this discrepancy is possibly mediated by the difference in
the epigenetic status between these two types of PS cells (30,
125). During the reprogramming, miRs also have roles in
epigenetic modifications that favor reprogramming. For ex-
ample, the Dlk1–Dio3 gene cluster, which includes *50 con-
served miRs, is often silenced in iPS cells (98, 161), and the
treatment by HDAC inhibitors of iPS cells led to activation of
theDlk1–Dio3 gene miR cluster to enhance the developmental
potential to be equivalent to that of ES cells (161). These
findings suggest that the appropriate epigenetic status of cells
needs to be achieved during the reprogramming, and further
reinforce the critical roles of miRs for establishing and main-
taining pluripotency. Additionally, inhibition or knock-down
of Dnmt enhanced iPS cell generation by inducing the de-
methylation of promoters of pluripotency-related genes (115).
Dnmt inhibitors were also used to generate iPS cells with only
two factors (Oct4 and Klf4) or three factors (Sox2, Oct4, and
Klf4) (63, 152). The targets of miR-29b, which induces global
DNA hypomethylation and re-expression of Ink4b tumor
suppressor gene, are Dnmt1, 3a, and 3b (51). Therefore, miR-
29b expression and Dnmt inhibitors is expected to enhance
reprogramming efficiency by promoting demethylation of
promoter regions of pluripotency-related genes. These results
indicate a critical role for miRs in reprogramming somatic
cells into iPS cells.
Epigenome reprogramming by small molecules
Strong evidence that epigenetic modifications are closely
related to the reprogramming of somatic cells is augmentation
of reprogramming efficiency by the use of small molecules in
generating iPS cells. In somatic cells, reprogramming factors
have highlymethylated endogenous loci. However, in ES cells
and iPS cells, these factors are hypomethylated (65). Their
promoters need to be demethylated in order to be reactivated
and thereby derive iPS cells. Direct reprogramming steps re-
quire downstream epigenetic modifiers because the direct
reprogramming factors lack demethylation activity. Differ-
ences in epigenetic modifiers such as CpG methylation be-
tween ES cells and lineage-specific ES cells emphasize
importance of epigenetic landscape in iPS cell generation. Doi
et al. (40) found that characterization of CpG methylation can
help in distinguishing the identity of cell types such as fi-
broblasts, ES cells, and iPS cells. Because chromatin re-
modeling is important for reprogramming, small molecules
are being used to overcome these epigenetic blocks and en-
hance iPS cell generation. Consequently, DNA and HMTs,
chemical inhibitors of HDACs, and genetic factors were used
in different combinations (63, 153). Ding and colleagues (83)
found that a small-molecule inhibitor ofG9aHMT, BIX-01294,
could enhance the induction of reprogramming in neural stem
cells while replacing Oct4. Since G9a is a down-regulator of
Oct4 during early development, they suggested that BIX-
01294 enhances iPS cell formation by inhibiting G9a and
subsequently releasing Oct4 from negative regulation. iPS
cells were generated from MEFs with only two factors, Oct4
and Klf4, in the presence of BIX-01294.
In a four-factor system, VPA increases the efficiency and
kinetics of reprogramming by a hundred fold. VPA can
chemically induce iPS cell generation with onlyOct4 and Sox2
from human fibroblasts (63) and it could replace either Klf4
or c-Myc in reprogramming steps. These results indicate that
DNA methylation, histone methylation, and histone deace-
tylation contribute to epigenetic hurdles which limit effective
iPS cell generation.
Conclusion
Recent advances in unbiased next-generation sequencing
methods for whole epigenome sequencing allowed mapping
of epigenetic marks at single-nucleotide resolution and led to
novel insights into the role of epigenetic changes in tran-
scriptional regulation and cell fate determination. In particu-
lar, epigenome sequencing of ES and iPS cells shed light on the
mechanisms governing maintenance and induction of plur-
ipotency. In addition, other advances have been made in re-
gard to the identification of PS cell-related miRs, their role in
reprogramming and maintenance of PS cells, and their inter-
action with other epigenetic modulators.
However, much more work needs to be done to fully un-
derstand the role of epigenetic modifications in PS cells. Parti-
cularly, the dynamic changes of chromatin state in responses to
the ectopic expression of transcription factors during the gen-
eration of iPS cells should be comprehensively investigated to
develop more efficient methods of reprogramming. New ap-
proaches for defining the epigenetic landscape are needed for a
better understanding of the chromatin structure and its role in
establishment of cell identity. A comprehensive epigenomic
map will also be helpful to determine the quality and utility
of directly reprogrammed or in vitro differentiated cells. Epi-
genome reference maps and data by the enormous increase in
sequencing capabilities will significantly facilitate our under-
standing of the epigenetic landscape of PS cells and their dy-
namic changes during reprogramming and differentiation.
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